treatment-related progressive multifocal leukoencephalopathy current understanding future steps abstract progressive multifocal leukoencephalopathy pml rare demyelinating disorder brain caused ubiquitous polyomavirus jc virus pml underlying immunosuppression acquired immune deficiency syndrome common predisposing disorder recently pharmacological agents demonstrated increase risk pml therapies predispose people pml classified categories therapies uniquely increase risk disorder monoclonal antibodies natalizumab efalizumab therapies increase risk individuals risk pml due pre-existing conditions rituximab mycophenolate mofetil therapies mechanism action suggest potential increased pml risk and/or rare cases pml observed unlike classes therapeutic agents uniquely increasing risk pml greater prevalence disorder latent interval time drug initiation development pml pml development pharmacological agents provided insight pathogenesis devastating disorder review focuses risks pml multiple pharmacological agents proposed pathogenesis agents potential risk mitigation strategies 
